Skip to main content
. Author manuscript; available in PMC: 2010 Dec 7.
Published in final edited form as: Circ Res. 2009 Oct 22;105(12):1248–1255. doi: 10.1161/CIRCRESAHA.109.208926

Figure 8. Effect of Ang II in NTS on baroreflex of SHR pretreated with either the LV-DNp85α or LV-eGFP.

Figure 8

Grouped values for the cardiac baroreflex gain (A) and sympathetic baroreflex gain (B) following Ang II injection in the NTS of the SHR pre-treated with either the control virus (LV-eGFP, grey bars) or the virus blocking the PI3-K activity (LV-DNP85α, white bars). Data are presented as percentage of control baroreflex gain (i.e. the gain measured prior to the Ang II injection). *P<0.05 and ***P<0.001 vs. control baroreflex gain.